biostudies-literatureUnknownOtto CBundesministerium für Bildung und ForschungBerlin Institute of HealthBerlin University AllianceStiftung Charité<h4>Objective</h4>To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations.<h4>Results</h4>Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations.<h4>Conclusion</h4>Additional vaccinations quaMultiple sclerosis (Houndmills, Basingstoke, England)13524585231161253https://www.ebi.ac.uk/biostudies/studies/S-EPMC10051002biostudies-literatureHumoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.PMC10051002BIH Clinical Fellow ProgramBIH-Charité Clinician Scientist Program01KI202101KX2021Otto CNiederschweiberer MWalper FJeworowski LMPache FSchindler PRuprecht KSchmidt MLSchwarz TDrosten CCorman VMKrumbholz ARose RfalseHumoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.<h4>Objective</h4>To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations.<h4>Results</h4>Frequencies of aCD20pwMS with detectable SARS-CoV-2-S1-IgG increased moderately between two (31/61 (51%)), three (31/57 (54%)), and four (17/26 (65%)) vaccinations. However, among patients with detectable SARS-CoV-2-S1-IgG, frequencies of high avidity (6/31 (19%) vs 11/17 (65%)) and Omicron neutralizing antibodies (0/10 (0%) vs 6/10 (60%)) increased strongly between two and four vaccinations. SARS-CoV-2-specific T cells were detectable in >92% after two or more vaccinations.<h4>Conclusion</h4>Additional vaccinations qua2023-01-01T00:00:00Z2023 Mar2025-05-29T14:38:02.359Z2025-02-19T00:49:41.191ZS-EPMC100510023697493810.1177/13524585231161253